Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has entered into a collaboration with TARA Mind, working alongside Veterans Exploring Treatment Solutions (VETS), to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting major depressive disorder. The partnership aims to expand mental health awareness within the veteran community while leveraging TARA Mind and VETS networks to enhance veteran engagement.
The collaboration aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness, as Helus advances its FDA Breakthrough Therapy-designated HLP003 program and broader pipeline of novel serotonergic agonists addressing unmet mental health needs. HLP003 is a proprietary novel serotonergic agonist (NSA) in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. The company also has HLP004, another NSA in Phase 2 for generalized anxiety disorder, and an extensive research portfolio of investigational NSAs.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company focused on developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to improve the treatment landscape by introducing NSAs that provide durable improvements in mental health.
The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. Helus Pharma is a trademark of Cybin Corp.
This collaboration is critical because it directly supports the recruitment of veterans into a Phase 3 trial for a Breakthrough Therapy-designated treatment, potentially accelerating access to a novel therapy for major depressive disorder in a population with high mental health needs. The partnership also highlights the growing focus on mental health treatments for veterans, supported by recent executive actions.
